World Health Organization. Breast Cancer. (2021). https://www.who.int/news-room/fact-sheets/detail/breast-cancer.

Larsen L. “I think it is a powerful campaign and does a great job of raising awareness in young women”: findings from breast cancer awareness campaigns targeting young women in Canada. Can Oncol Nurs J. 2022;32:61–67. https://doi.org/10.5737/236880763216167.

Article  PubMed  PubMed Central  Google Scholar 

Gompel A, Chaouat M, Mebarki S, Keneck B. Hormone receptor-positive, HER2-negative breast cancer: current and new therapeutic approaches. Cancer Treat Rev. 2020;91:102113.

Google Scholar 

Shah AN, Metzger O, Bartlett CH, Liu Y, Huang X, Cristofanilli M. Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. Oncologist. 2020;25:e900–e908. https://doi.org/10.1634/theoncologist.2019-0729.

Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12.

Article  CAS  PubMed  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2015;375:1925–36.

Article  Google Scholar 

Cejuela M, Gil-Torralvo A, Castilla MN, Domínguez-Cejudo MN, Falcón A, Benavent M, et al. Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer. Int J Mol Sci. 2023;24:8488. https://doi.org/10.3390/ijms24108488.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46.

Article  CAS  PubMed  Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.

Article  CAS  PubMed  Google Scholar 

Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in hormone-receptor-positive, advanced breast cancer. J Clin Oncol. 2017;35:2875–84.

Article  CAS  PubMed  Google Scholar 

Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015;21:4760–6. https://doi.org/10.1158/1078-0432.CCR-15-1185.

Wedam S, Fashoyin-Aje L, Bloomquist E, Tang S, Sridhara R, Goldberg KB, et al. FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020;26:1208–12. https://doi.org/10.1158/1078-0432.

Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive, HER2-negative, advanced breast cancer: PALOMA-1, a randomized phase 2 trial. Lancet Oncol. 2016;17:425–39.

Google Scholar 

Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther. 2016;15:2273–81.

Article  PubMed  Google Scholar 

Hafner M, Mills CE, Subramanian K, Chen C, Chung M, Boswell SA, et al. Multi-omics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26:1067–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu H, Schulze-Gahmen U. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J Med Chem. 2006b;49(13):3826–31. https://doi.org/10.1021/jm0600388.

Article  CAS  PubMed  Google Scholar 

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kuter I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35. https://doi.org/10.1016/S1470-2045(14)71159-3.

Article  CAS  PubMed  Google Scholar 

Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2018;379:1926–36. https://doi.org/10.1056/NEJMoa1800159.

Article  CAS  PubMed  Google Scholar 

Liu Y, Zhang W, Wang X. Mechanisms of action and therapeutic efficacy of CDK4/6 inhibitors in cancer treatment: a review. Cancer Res. 2018;78:2930–9. https://doi.org/10.1158/0008-5472.CAN-18-0165.

Article  Google Scholar 

Richardson PG, Schlossman RL, Jagannath S, Hideshima T, Lentzsch S, Mitsiades C, et al. Phase I/II study of palbociclib in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Blood. 2018;131:263–72. https://doi.org/10.1182/blood-2017-08-798710.

Article  Google Scholar 

Xiang J, Wu Y, Zhao X. Palbociclib in lung squamous cell carcinoma: STAT3 signaling inhibition and apoptosis induction. Cancer Res. 2022;82:823–32. https://doi.org/10.1158/0008-5472.CAN-21-1125.

Article  Google Scholar 

Pensa S, Nenci A, Poli V. STAT3 as a therapeutic target in inflammation and cancer. Curr Opin Oncol. 2009;21:317–25. https://doi.org/10.1097/CCO.0b013e32832a5d79.

Article  Google Scholar 

Samavati L, Rastogi R, Duan X, Wang Y. IL-1β and IL-6 induced STAT3 activation: signaling pathways in lung cancer. J Immunol. 2009;183:646–53. https://doi.org/10.4049/jimmunol.0900593.

Article  Google Scholar 

Kang Y, Massagué J, Miyamoto T. Myc and survivin in cancer cell survival: a review. Cell. 2014;156:952–64. https://doi.org/10.1016/j.cell.2014.02.015.

Article  CAS  Google Scholar 

Samavati L, Rastogi R, Du W, Hüttemann M, Fite A, Franchi L. STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol. 2009;46:1867–77. https://doi.org/10.1016/j.molimm.2009.02.018.

Article  CAS  PubMed  Google Scholar 

Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, et al. Pyrido[2,3-d]pyrimidin-7-one inhi-bitors of cyclin-dependent kinases. J Med Chem. 2001;44:1016. https://doi.org/10.1021/jm010012a.

Article  CAS  Google Scholar 

Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 2005;48:2388–406. https://doi.org/10.1021/jm049354h.

Article  CAS  PubMed  Google Scholar 

Toogood PL, Ide ND. Palbociclib (Ibrance): the first-in-class CDK4/6 inhibitor for breast cancer. In: Innovative drug synthesis. John Wiley and Sons, Inc; 2015. pp. 167–96.

Erdman DT, Flamme CM, Nelson JD. Synthesis of 2-(pyridine-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones. PCT Int Appl. 2008. WO 032157 A2.

Maloney MT, Jones BP, Olivier MA, Magano J, Wang K, Ide ND, et al. Palbociclib commercial manufacturing process development. Part II: regioselective heck coupling with polymorph control for processability. Org Process Res Dev. 2016;20:1203–16. https://doi.org/10.1021/acs.oprd.6b00069.

Article  CAS  Google Scholar 

Chekal BP, Ewers J, Guinness SM, Ide ND, Leeman KR, Post RJ, et al. Palbociclib commercial manufacturing process development. Part III. deprotection followed by crystallization for API particle property control. Org Process Res Dev. 2016;20:1217–26. https://doi.org/10.1021/acs.oprd.6b00071.

Article  CAS  Google Scholar 

Duan S, Place D, Perfect HH, Ide ND, Maloney M, Sutherland K, et al. Palbociclib commercial manufacturing process development. Part I: control of regioselectivity in a grignard-mediated SNAr coupling. Org Process Res Dev. 2016;20:1191–202. https://doi.org/10.1021/acs.oprd.6b00070.

Article  CAS  Google Scholar 

Sai KKS, Gilbert TM, Klumpp DA. J Org Chem. 2007;72:9761–4.

Article  CAS  PubMed  Google Scholar 

Kienle M, Dubbaka SR, Brade K, Knochel P. J Org Chem. 2007;20:4166–76.

Google Scholar 

Marco-Contelles J, Pérez-Mayoral E, Samadi A, do Carmo Carreiras M, Soriano E. Chem Rev. 2009;109:2652–71.

Article  CAS  PubMed  Google Scholar 

Kadnikov DV, Larock RC. J Org Chem. 2004;69:6772–80.

Article  CAS  PubMed  Google Scholar 

Li T, Zhou AD, Bai LF, Zhang XY, Zhou YT, Yang HL, et al. Design, synthesis, and anticancer activity of three novel palbociclib derivatives. Front Oncol. 2022;12:959322. https://doi.org/10.3389/fonc.2022.959322.

Article  CAS  PubMed  PubMed Central